News

PharmiWeb6d
Allergic Rhinitis Drugs Market Analysis (2024-2035)
Market OverviewThe global Allergic Rhinitis Drugs Market is valued at USD 1.90 Billion in 2024 and is projected to reach a ...
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...
Irish Medical Times11d
ALK’s allergy treatment ACARIZAX (12-SQ-HDM SLIT) now approved for children aged 5+ in Ireland
Studies suggest that allergic rhinitis is the most common allergic condition ...
Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published ...
Health on MSN9d
What's the Difference Between Allergies and a Sinus Infection?
Allergies and sinus infections can cause many similar symptoms, such as nasal congestion. However, the conditions have ...
‘Hayfever made me miserable - until I discovered this cheap natural remedy'
With nearly half of the UK population suffering from hay fever, also known as allergic rhinitis, the beginning of a new ...
5 drinks that could help hay fever symptoms amid pollen bomb
Peppermint tea and orange juice could be the answer to helping “wash out allergens” to alleviate hay fever symptoms during Met ...
Medindia11d
New Study Demonstrates Efficacy and Safety of SEBclausii (Alkalihalobacillus clausii 088AE) in Treating Acute Allergic Rhinitis
A recently published clinical trial found probiotic SEBclausii� (Alkalihalobacillus clausii 088AE) from Specialty Enzymes & Probiotics supports the alleviation of symptoms of acute allergic rhinitis.